Czech Republic Pharmaceuticals & Healthcare Report Q3 2018
The Czech Republic will remain one of the most attractive markets for innovative drugmakers in Central and EasternEurope due to increasing demand for higher-value medicines. We note, however, that a lack of generic medicine uptake posesconsiderable risks to market sustainability, posing downside risks to long-term market growth. Moreover, the market poses feweropportunities for increased FDI by multinational innovative pharmaceutical firms into manufacturing than its regional peers,although investment into clinical trials is likely to remain robust.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook